On August 25, Guo Guangchang, chairman of Fosun, answered investors' questions on the approval progress of COVID-19 's mRNA vaccine Fubitai at an interim results conference in 2021, saying that the approval of the vaccine is making normal progress and is fair and transparent in terms of procedures. CDE and the FDA have given Fosun a lot of support. At the same time, he said that the vaccine is not all of Fosun, it is only a product of Shanghai Fosun Pharmaceutical, the vaccine is to give everyone one more choice, no matter what the outcome.
复星国际董事长：新冠mRNA疫苗复必泰审批进展正常
Chairman Fosun: COVID-19 mRNA Vaccine Fubitai has made normal progress in examination and approval.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.